RS58704B1 - Pirazolo[1,5-a]pirimidin-5,7-diamin jedinjenja kao cdk inhibitori i njihova terapeutska primena - Google Patents
Pirazolo[1,5-a]pirimidin-5,7-diamin jedinjenja kao cdk inhibitori i njihova terapeutska primenaInfo
- Publication number
- RS58704B1 RS58704B1 RS20190487A RSP20190487A RS58704B1 RS 58704 B1 RS58704 B1 RS 58704B1 RS 20190487 A RS20190487 A RS 20190487A RS P20190487 A RSP20190487 A RS P20190487A RS 58704 B1 RS58704 B1 RS 58704B1
- Authority
- RS
- Serbia
- Prior art keywords
- pyrazolo
- pyrimidine
- therapeutic use
- diamine compounds
- cdk inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201403093A GB201403093D0 (en) | 2014-02-21 | 2014-02-21 | Therapeutic compounds and their use |
| PCT/GB2015/050494 WO2015124941A1 (en) | 2014-02-21 | 2015-02-20 | Pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds as cdk inhibitors and their therapeutic use |
| EP15706282.9A EP3107914B8 (en) | 2014-02-21 | 2015-02-20 | Pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds as cdk inhibitors and their therapeutic use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS58704B1 true RS58704B1 (sr) | 2019-06-28 |
Family
ID=50482596
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20190487A RS58704B1 (sr) | 2014-02-21 | 2015-02-20 | Pirazolo[1,5-a]pirimidin-5,7-diamin jedinjenja kao cdk inhibitori i njihova terapeutska primena |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US9932344B2 (sr) |
| EP (1) | EP3107914B8 (sr) |
| JP (1) | JP6498212B2 (sr) |
| CN (1) | CN106103445B (sr) |
| AU (1) | AU2015220560B2 (sr) |
| BR (1) | BR112016018633B1 (sr) |
| CA (1) | CA2939786C (sr) |
| CY (1) | CY1121588T1 (sr) |
| DK (1) | DK3107914T3 (sr) |
| ES (1) | ES2721268T3 (sr) |
| GB (1) | GB201403093D0 (sr) |
| HR (1) | HRP20190685T1 (sr) |
| HU (1) | HUE043122T2 (sr) |
| LT (1) | LT3107914T (sr) |
| ME (1) | ME03427B (sr) |
| NZ (1) | NZ724323A (sr) |
| PL (1) | PL3107914T3 (sr) |
| PT (1) | PT3107914T (sr) |
| RS (1) | RS58704B1 (sr) |
| SI (1) | SI3107914T1 (sr) |
| TR (1) | TR201905647T4 (sr) |
| WO (1) | WO2015124941A1 (sr) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201403093D0 (en) | 2014-02-21 | 2014-04-09 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| AU2015337607B2 (en) | 2014-10-31 | 2020-04-09 | Ube Corporation | Substituted dihydropyrrolopyrazole compound |
| BR112017012588B8 (pt) | 2014-12-17 | 2024-03-05 | King S College London | Compostos heteroaril-heteroarila bicíclicos de ácido benzoico, seus usos, composições farmacêuticas, métodos de preparação destas e métodos para provocar ou promover o desenvolvimento de neuritos, o crescimento de neuritos e/ou a regeneração de neuritos e para ativar o receptor beta do ácido retinoico |
| EP3256475A4 (en) * | 2015-02-13 | 2019-02-13 | Dana-Farber Cancer Institute, Inc. | LRRK2 INHIBITORS AND METHOD FOR THE PRODUCTION AND USE THEREOF |
| EP3309163A4 (en) | 2015-06-15 | 2019-01-09 | UBE Industries, Ltd. | SUBSTITUTED DIHYDROPYRROLO PYRAZOL DERIVATIVE |
| US20200123499A1 (en) | 2015-12-02 | 2020-04-23 | Massachusetts Institute Of Technology | Method for efficient generation of neurons from non-neuronal cells |
| SG11201901747VA (en) | 2016-08-31 | 2019-03-28 | Agios Pharmaceuticals Inc | Inhibitors of cellular metabolic processes |
| MX2020001103A (es) | 2017-07-28 | 2020-08-17 | Nimbus Lakshmi Inc | Inhibidores de tirosina cinasa 2 (tyk2) y usos de los mismos. |
| KR20200051626A (ko) * | 2017-08-07 | 2020-05-13 | 조인트 스탁 컴퍼니 "바이오케드" | Cdk8/19 저해제로서 새로운 헤테로사이클릭 화합물 |
| WO2019035866A1 (en) * | 2017-08-15 | 2019-02-21 | The Brigham & Women's Hospital, Inc. | COMPOSITIONS AND METHODS FOR TREATING THE TUBEROUS SCLEROSIS COMPLEX |
| GB201715194D0 (en) | 2017-09-20 | 2017-11-01 | Carrick Therapeutics Ltd | Compounds and their therapeutic use |
| TWI703149B (zh) * | 2017-11-16 | 2020-09-01 | 美商美國禮來大藥廠 | 用於抑制cdk7之化合物 |
| JP2021521120A (ja) * | 2018-04-11 | 2021-08-26 | キュリエント カンパニー， リミテッド | サイクリン依存性キナーゼの選択的インヒビターとしてのピラゾロ−トリアジン誘導体および／またはピラゾロ−ピリミジン誘導体 |
| WO2019213403A1 (en) | 2018-05-02 | 2019-11-07 | Kinnate Biopharma Inc. | Inhibitors of cyclin-dependent kinases |
| WO2020006497A1 (en) | 2018-06-29 | 2020-01-02 | Kinnate Biopharma Inc. | Inhibitors of cyclin-dependent kinases |
| CN112996790B (zh) | 2018-10-30 | 2023-11-03 | 克洛诺斯生物公司 | 用于调节cdk9活性的化合物、组合物和方法 |
| EP3885347B1 (en) | 2018-11-14 | 2023-11-22 | UBE Corporation | Dihydropyrrolopyrazole derivative |
| CN109860354B (zh) | 2018-12-28 | 2020-05-19 | 南京邮电大学 | 同质集成红外光子芯片及其制备方法 |
| WO2020186196A1 (en) * | 2019-03-13 | 2020-09-17 | The Translational Genomics Research Institute | Trisubstituted pyrazolo [1,5-a] pyrimidine compounds as cdk7 inhibitors |
| WO2021003517A1 (en) * | 2019-07-10 | 2021-01-14 | Aucentra Therapeutics Pty Ltd | Derivatives of 4-(imidazo[l,2-a]pyridin-3-yl)-n-(pyridinyl)pyrimidin- 2-amine as therapeutic agents |
| AU2020374961A1 (en) * | 2019-10-29 | 2022-05-26 | Syros Pharmaceuticals, Inc. | Methods of treating cancer in biomarker-identified patients with inhibitors of cyclin-dependent kinase 7 (CDK7) |
| GB201918541D0 (en) * | 2019-12-16 | 2020-01-29 | Carrick Therapeutics Ltd | Therapeutic compounds and their use |
| JP2023517034A (ja) * | 2020-03-06 | 2023-04-21 | バイエル アクチェンゲゼルシャフト | Ｃｄｋ１２の阻害を介してがんに作用するイミダゾトリアジン |
| US20230158159A1 (en) * | 2020-04-24 | 2023-05-25 | Massachusetts Institute Of Technology | Chimeric degraders of cyclin-dependent kinase 9 and uses thereof |
| AU2022211514A1 (en) * | 2021-01-22 | 2023-09-07 | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | Substituted pyrazolo[1,5-a]pyrimidine-7-amine derivative, and compositions and medical use thereof |
| WO2023001061A1 (en) * | 2021-07-17 | 2023-01-26 | Jingrui Biopharma Co., Ltd. | Cdk7 selective inhibitors as anticancer agents |
| WO2023096922A1 (en) * | 2021-11-24 | 2023-06-01 | Kronos Bio, Inc. | Polymorphic and salt forms of (ls,3s)-n1-(5-(pentan-3- yl)pyrazolo[l,5-a]pyrimidin-7-yl)cyclopentane-l,3-diamine |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60043397D1 (de) | 1999-12-28 | 2010-01-07 | Pharmacopeia Inc | Cytokine, insbesondere tnf-alpha, hemmer |
| WO2004022561A1 (en) | 2002-09-04 | 2004-03-18 | Schering Corporation | Pyrazolopyrimidines as cyclin-dependent kinase inhibitors |
| CA2513684A1 (en) | 2003-01-31 | 2004-08-19 | Merck & Co., Inc. | 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| MXPA05008955A (es) | 2003-02-28 | 2006-02-22 | Teijin Pharma Ltd | Derivados de pirazolo [1,5-a] pirimidina. |
| WO2004087707A1 (en) | 2003-03-31 | 2004-10-14 | Vernalis (Cambridge) Limited | Pyrazolopyrimidine compounds and their use in medicine |
| JO2478B1 (en) | 2003-06-19 | 2009-01-20 | جانسين فارماسوتيكا ان. في. | (Aminomethyl) -biperidine benzamides as 5 HT4 antagonists |
| TWI421078B (zh) * | 2005-10-06 | 2014-01-01 | Merck Sharp & Dohme | 關卡激酶抑制劑及其用途 |
| AU2008261027A1 (en) * | 2007-06-05 | 2008-12-11 | Emory University | Selective inhibitors for cyclin-dependent kinases |
| ES2629170T3 (es) * | 2009-12-04 | 2017-08-07 | Senhwa Biosciences, Inc. | Pirazolopirimidinas y heterociclos relacionados como inhibidores de CK2 |
| WO2012059932A1 (en) | 2010-11-01 | 2012-05-10 | Aurigene Discovery Technologies Limited | 2, 4 -diaminopyrimidine derivatives as protein kinase inhibitors |
| ES2834093T3 (es) * | 2011-07-21 | 2021-06-16 | Sumitomo Dainippon Pharma Oncology Inc | Inhibidores de proteína quinasa heterocíclicos |
| EP2634190A1 (en) | 2012-03-01 | 2013-09-04 | Lead Discovery Center GmbH | Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhinitors |
| EP2634189A1 (en) | 2012-03-01 | 2013-09-04 | Lead Discovery Center GmbH | Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhibitors |
| GB201403093D0 (en) | 2014-02-21 | 2014-04-09 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
-
2014
- 2014-02-21 GB GB201403093A patent/GB201403093D0/en not_active Ceased
-
2015
- 2015-02-20 DK DK15706282.9T patent/DK3107914T3/en active
- 2015-02-20 ME MEP-2019-119A patent/ME03427B/me unknown
- 2015-02-20 PL PL15706282T patent/PL3107914T3/pl unknown
- 2015-02-20 EP EP15706282.9A patent/EP3107914B8/en active Active
- 2015-02-20 WO PCT/GB2015/050494 patent/WO2015124941A1/en active Application Filing
- 2015-02-20 US US15/117,982 patent/US9932344B2/en active Active
- 2015-02-20 ES ES15706282T patent/ES2721268T3/es active Active
- 2015-02-20 CN CN201580011502.7A patent/CN106103445B/zh active Active
- 2015-02-20 TR TR2019/05647T patent/TR201905647T4/tr unknown
- 2015-02-20 AU AU2015220560A patent/AU2015220560B2/en active Active
- 2015-02-20 RS RS20190487A patent/RS58704B1/sr unknown
- 2015-02-20 PT PT15706282T patent/PT3107914T/pt unknown
- 2015-02-20 SI SI201530714T patent/SI3107914T1/sl unknown
- 2015-02-20 CA CA2939786A patent/CA2939786C/en active Active
- 2015-02-20 LT LTEP15706282.9T patent/LT3107914T/lt unknown
- 2015-02-20 HU HUE15706282A patent/HUE043122T2/hu unknown
- 2015-02-20 NZ NZ724323A patent/NZ724323A/en unknown
- 2015-02-20 JP JP2016553387A patent/JP6498212B2/ja active Active
- 2015-02-20 BR BR112016018633-8A patent/BR112016018633B1/pt active IP Right Grant
-
2018
- 2018-03-30 US US15/941,063 patent/US10414772B2/en active Active
-
2019
- 2019-04-11 HR HRP20190685TT patent/HRP20190685T1/hr unknown
- 2019-04-17 CY CY20191100425T patent/CY1121588T1/el unknown
- 2019-09-04 US US16/559,735 patent/US10927119B2/en active Active
-
2021
- 2021-02-15 US US17/175,780 patent/US11566029B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME03427B (me) | Pirazolo[1,5-a]pirimidin-5,7-diamin jedinjenja kao cdk inhibitori i njihova terapeutska primjena | |
| HK1258157A1 (zh) | 作為jak抑制劑的吡唑並[1，5-a]吡嗪-4-基衍生物 | |
| IL254224A0 (en) | 7-substituted 5-alkyl-[4,2,1]triazolo[5,1-a]pyrimidine derivatives as pde2 inhibitors | |
| HK1256751A1 (zh) | [1，2，4]三唑並[1，5-a]嘧啶-7-基化合物 | |
| IL247947B (en) | 7,6,5,4-tetrahydro-pyrazolo[5,1-a]pyrazine compounds and 8,7,6,5-tetrahydro-h4-pyrazolo[5,1-a][4,1]diazepine compounds as ros1 inhibitors | |
| HK1254809A1 (zh) | 治療中有用的吡唑並[1，5-a]三嗪-4-胺衍生物 | |
| HK1225723A1 (zh) | 取代的咪唑並[1，2-a]吡啶甲酰胺及其用途 | |
| HRP20180788T1 (hr) | [1,2,4]triazolo[4,3-b]piridazini za uporabu za liječenje proliferativnih bolesti | |
| HK1254651A1 (zh) | 吡唑並[1，5-a]嘧啶-3-甲酰胺的環醚衍生物 | |
| IL253427B (en) | The result of pyrazolo[3,4-d]pyrimidine and its use in the treatment of Jericho rose |